Current status of breast cancer chemoprevention;Quimioprevenção do câncer de mama

Revista da Associacao Medica Brasileira

Volumn 52, Issue 6, 2006, Pages 453-459

  De Oliveira, Vilmar Marques ^a   Aldrighi, José Mendes ^a   Rinaldi, José Francisco ^a  

^a NONE

Author keywords

Aromatase; Breast cancer; Chemoprevention; Cyclooxygenase; Raloxifene; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE; PROSTAGLANDIN SYNTHASE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; RISK;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RALOXIFENE; RISK; TAMOXIFEN;

EID: 33846811677     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302006000600028     Document Type: Article

References (41)

1. Johnson-Thompson MC, Guthrie J. Ongoing research to identify environmental risk factors in breast carcinoma. Cancer. 2000;88:1224-9.
2. Feuer EJ, Wun L, Boring CC, Flaunders WD, Timmel MJ, Tong T. The life time risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892-97.
3. Brasil. Ministério da Saúde INCA/Comprev. Estimativa 2006: Incidência de câncer no Brasil. Rio de Janeiro; 2005.
4. Bilimoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. Cancer J Clin. 1995;45:263-78.
5. Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-g. Int J Oncol. 2002;20:1109-22.
6. Molina LA, Dalben I, Luca LA. Análise das oportunidades de diagnóstico precoce para as neoplasias malignas de mama. Rev Assoc Med Bras. 2003;49:185-90.
7. Prichard RS, Hill ADK, Dijkstra B, Mcdermott EW, O'higgins NJ. The chemoprevention of breast cancer. British J Surg. 2003;90:772-83.
8. Sporn MB. Approaches to prevention of the epithelial cancer during the pre-neoplastic period. Cancer Res. 1976;36:2699-702.
9. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2:282-4.
10. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than 5 years of tamoxifen for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529-42.
11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.
12. Powles T, Eeles R, Ashley SE, Easton D, Chang J, Dowsett L. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98-101.
13. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359:1122-24.
14. Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet. 2002;360:817-24.
15. Gail MH, Brinton LA, Byar DP. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-86.
16. Fisher B, Constantino JP, Wickerham: J Natl Cancer Inst. 2005;97:1652-1662.
17. Cuzick J, Powles T, Verones U, Forbes J, Edwards R, Ashley, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
18. Jordan, VC, Morrow M. Tamoxifen, raloxifen, and the prevention of breast cancer. Endocr Rev. 1999;20:253-78.
19. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie Dw. Continued breast cancer risk reduction in postmenopausal women treated with raloxifen. Breast Cancer Res Treat. 2001;65:125-34.
20. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-61.
21. Vogel V, Constantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727-41.
22. Purohit A, Newman SP, Reed MJ. The role of cytoquines in regulating estrogen synthesis. implications for the etiology of breast cancer. Breast Cancer Res. 2002;4:65-69.
23. Pasqualini, JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talb I M, et al. Concentrations of estrone, estradiol, and estronesulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1996;81:1460-4.
24. Sun X.Z., Zhou D; Chen S. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 andT-47D cells. J Steroid Biochem Mol Biol. 1997;63:29-36.
25. Castagnetta LA, Lo Casto M, Granata OM, Polito L, Calabro M, Lo BA, et al. Estrogen content and metabolism in human breast tumor tissue and cells. Ann NY Acad Sci. 1996;784:314-24.
26. ATAC trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-2.
27. Wagner JD, Anthony MS, Cline JM. Soy phytoestrogens: research on benefits and risks. Clin Obstet Gynecol. 2001;44:843-52.
28. Horn-Ross P, John E, Lee M.. Phytoestrogen consumption and breast cancer risk in a multiethnic population. Am J Epidemiol. 2001;154: 434-41
29. Hawk ET, Viner JL, Asad Umar A, William F, Anderson WF, Sigman CC, et al. Development of COX inhibitors in cancer prevention and therapy. Am J Cancer. 2003;2:27-55.
30. Dempke W, Rie C, Grothey A, Schmoll H. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127:411-7.
31. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3-21.
32. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996;88:988-93.
33. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1586-91.
34. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71-3.
35. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001;84:1188-92.
36. Zhang Z, Yamshita H, Toyama T, Hara Y, Omoto Y, Sugiura H, et al. Semi-quantitative immunohistochemical analysis of aromatase expression in cuctal carcinoma of the breast. Breast Cancer Res Treat. 2002;74: 47-53.
37. Harris RE, Beebe-Donk J, Alshafie A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006;6:27.
38. Simeone AM, Tari AM How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci. 2004;61:1475-84.
39. Veronesi U, Palo G, Marubini E, Costa A, Formelli F, Mariani L, et al. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer. J Natl Cancer Inst. 1999;91:1847-56.
40. Kochhar R, Khurana V, Bejjanki H. Statins reduce breast cancer risk: A case control study in US female veterans. J Clin Oncol. 2005;23:7S.
41. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606-12.